re: cancer trial update - skint
These progress results are good . I would have liked to see more NSCLC patients in the trial . They have seen a response out of the only NSCLC patient to complete the treatment . That is 100% so far , against that type of cancer . Rational Therapeutics assay tests revealed NSCLC as the best target for BEC(coramsine) and it looks like he was right on the money . I will be interested to see his ongoing research .Treatment is yet to be completed on that NSCLC patient . Further improvement may be seen . The immune system reaction is yet to be seen as it contributes to longterm survival . To show a response against a late stage NSCLC patient is big news . The IMOxine combination is yet to be trialed , but indications are it will make the Coramsine more potent . A breakthrough against NSCLC , still a possibility here , could save thousands of lives each year . All IMHO
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
